search
Back to results

Transcutaneous Vagal Nerve Stimulation in Veterans With Posttraumatic Stress Disorder (VNS in PTSD)

Primary Purpose

Stress Disorders, Post-Traumatic

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
tcVNS
sham
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stress Disorders, Post-Traumatic focused on measuring Stress Disorders, Post-Traumatic, PTSD, Vagus Nerve

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Veterans between the ages of 18 and 75 will be included with a diagnosis of PTSD based on DSM-5 criteria

Exclusion Criteria:

Subjects will be excluded with:

  • a history of mild traumatic brain injury (mTBI) based on VA Criteria
  • moderate or greater TBI
  • positive pregnancy test
  • meningitis or other neurological disorder
  • alcohol or substance abuse use disorder based on DSM-5 criteria within the past 12 months
  • current or lifetime history of schizophrenia, schizoaffective disorder, bipolar I disorder, anorexia nervosa or bulimia, based on DSM-5
  • active suicidal ideation with a plan
  • a history of serious medical or neurological illness, such as cardiovascular, gastrointestinal, hepatic, renal, neurologic or other systemic illness that would preclude participation based on clinical judgment of the PI
  • active opiate or benzodiazepine treatment
  • history of structural abnormality on brain MRI or CT if one has been performed in the past

Sites / Locations

  • Atlanta VA Medical and Rehab Center, Decatur, GARecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

tcVNS

sham

Arm Description

Stimulation twice daily with transcutaneous Vagal Nerve Stimulation (tcVNS)

stimulation with sham

Outcomes

Primary Outcome Measures

Change in PTSD symptoms
Change in PTSD symptoms measured with the Clinician Administered PTSD Scale (CAPS) and PTSD Checklist (PCL) in tcVNS versus sham conditions
brain
change in brain activation in insula measured with PET in response to trauma scripts with VNS compared to sham

Secondary Outcome Measures

sympathetic function
change in pre-ejection period (PEP) during traumatic scripts with VNS compared to sham. PEP is the time from ventricular contraction to aortic valve opening and is a measure of cardiac sympathetic tone
interleukin-6
change in interleukin 6 concentration in blood in response to traumatic scripts with stimulation with VNS versus stimulation with sham

Full Information

First Posted
August 15, 2022
Last Updated
May 17, 2023
Sponsor
VA Office of Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT05517304
Brief Title
Transcutaneous Vagal Nerve Stimulation in Veterans With Posttraumatic Stress Disorder
Acronym
VNS in PTSD
Official Title
Transcutaneous Vagal Nerve Stimulation in Veterans With Posttraumatic Stress Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2022 (Actual)
Primary Completion Date
July 1, 2026 (Anticipated)
Study Completion Date
September 15, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study effects the effects of transcutaneous cervical vagal nerve stimulation (tcVNS) or a sham control on brain, physiology, and PTSD symptoms in Veterans with posttraumatic stress disorder (PTSD). Veterans undergo brain imaging and physiological measures in conjunction with traumatic scripts before and after three months of twice daily treatment with tcVNS or sham stimulation at home.
Detailed Description
Description: This study assesses brain function measured with High Resolution Positron Emission Tomography (HR-PET) during exposure to stressful traumatic scripts paired with tcVNS or sham stimulation, with secondary measures of blood inflammatory biomarkers, and sympathetic function. Participants then undergo three months of twice daily home treatment with repeat measures. Drug/Device Handling: [O-15] radiolabeled water has a half-life of 110 seconds and is made on site at the Emory Center for Systems Imaging (CSI). Dr. Bremner holds the Investigational New Drug (IND) approval for use of radiolabeled water at Emory University. The investigators have performed hundreds of studies in human subjects at Emory and there have been no adverse events or untoward effects to date. tcVNS with the GammaCore device is approved by the Emory IRB for a recently completed study in PTSD and others in progress for Opioid Use Disorder and was shown to be well tolerated and there have been no adverse events or untoward effects with the device. The FDA granted Breakthrough Device Designation for PTSD for the gammaCore tcVNS device based on the investigators' studies. Devices are blinded by ElectroCore and the devices and information are kept by the Data Manager under double lock and key. Device records are kept by the Data Manager and stored on Redcap or secured research drives. Devices are given to the study team along with a device schedule under direct supervision from the investigator.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stress Disorders, Post-Traumatic
Keywords
Stress Disorders, Post-Traumatic, PTSD, Vagus Nerve

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
tcVNS versus sham stimulation
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
sham stimulation comparison
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
tcVNS
Arm Type
Experimental
Arm Description
Stimulation twice daily with transcutaneous Vagal Nerve Stimulation (tcVNS)
Arm Title
sham
Arm Type
Active Comparator
Arm Description
stimulation with sham
Intervention Type
Device
Intervention Name(s)
tcVNS
Intervention Description
active stimulation with transcutaneous Vagal Nerve Stimulation (tcVNS)
Intervention Type
Device
Intervention Name(s)
sham
Intervention Description
sham stimulation
Primary Outcome Measure Information:
Title
Change in PTSD symptoms
Description
Change in PTSD symptoms measured with the Clinician Administered PTSD Scale (CAPS) and PTSD Checklist (PCL) in tcVNS versus sham conditions
Time Frame
Baseline to three months
Title
brain
Description
change in brain activation in insula measured with PET in response to trauma scripts with VNS compared to sham
Time Frame
baseline
Secondary Outcome Measure Information:
Title
sympathetic function
Description
change in pre-ejection period (PEP) during traumatic scripts with VNS compared to sham. PEP is the time from ventricular contraction to aortic valve opening and is a measure of cardiac sympathetic tone
Time Frame
baseline
Title
interleukin-6
Description
change in interleukin 6 concentration in blood in response to traumatic scripts with stimulation with VNS versus stimulation with sham
Time Frame
baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Veterans between the ages of 18 and 75 will be included with a diagnosis of PTSD based on DSM-5 criteria Exclusion Criteria: Subjects will be excluded with: a history of mild traumatic brain injury (mTBI) based on VA Criteria moderate or greater TBI positive pregnancy test meningitis or other neurological disorder alcohol or substance abuse use disorder based on DSM-5 criteria within the past 12 months current or lifetime history of schizophrenia, schizoaffective disorder, bipolar I disorder, anorexia nervosa or bulimia, based on DSM-5 active suicidal ideation with a plan a history of serious medical or neurological illness, such as cardiovascular, gastrointestinal, hepatic, renal, neurologic or other systemic illness that would preclude participation based on clinical judgment of the PI active opiate or benzodiazepine treatment history of structural abnormality on brain MRI or CT if one has been performed in the past
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Doug J Bremner, MD
Phone
(404) 712-9569
Email
James.Bremner@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Doug J Bremner, MD
Organizational Affiliation
Atlanta VA Medical and Rehab Center, Decatur, GA
Official's Role
Principal Investigator
Facility Information:
Facility Name
Atlanta VA Medical and Rehab Center, Decatur, GA
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30033-4004
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ashley N Scales
Phone
404-321-6111
Ext
23952
Email
Ashley.Scales@va.gov
First Name & Middle Initial & Last Name & Degree
Doug J Bremner, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
de identified data will be made available three months after study completion
IPD Sharing Time Frame
three months after study completion
IPD Sharing Access Criteria
three months after study completion for twelve months

Learn more about this trial

Transcutaneous Vagal Nerve Stimulation in Veterans With Posttraumatic Stress Disorder

We'll reach out to this number within 24 hrs